当前位置:循环首页>正文

[EuroPCR 2012]根据基因型和表型选择口服血小板P2Y12受体拮抗剂的方法——法国巴黎Pitié-Salpétrière 医院Jean-Philippe Collet教授专访

作者:  J.P.Collet   日期:2012/5/28 17:41:18

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

第一个标准是药物要有PCI的适应证。如果有适应证,就没有问题。第二个标准是当地的报销限制,因为新药的价格昂贵,并不是很多地方都能报销。

   International Circulation: As we all know DAPT is very important for post-PCI patients, what are the criteria for choosing appropriate P2Y12 receptor blockers?

  Dr. Collet: The first criteria is the label of the drug. If you are in the labeling, there is no problem. The second criteria is the local constraints because the new drugs are expensive and not available everywhere.
  Making the assumption that all drugs are available and that there are no money constraints, then the method of choosing drugs will depend on the risk of your patients. If you are off-label and this may happen some of the times, you need to have a careful assessment of the clopidogrel resistance of your patients. You may have very high-risk patients who are diabetics, who are having regular intervention while being on clopidogrel and overweight who would be good candidates for the P2Y12 inhibitors.
  The main example is peristalsis stent thrombosis. You may have some patients with history of  peristalsis stent thrombosis who present on DAPT with clopidogrel and probably they are good candidates to be switched to the new one because you may face a new stent thrombosis.
  I think we need to be clear and have simple clinical characteristics, which are related to clopidogrel resistance, which are diabetes, ACS presentation, and the type of lesion you are presented with. It would be very easy to make up your mind on which treatment to choose.
  《国际循环》:我们都知道双联抗血小板治疗(DAPT)对于PCI术后患者是非常重要的,选择合适的P2Y12受体拮抗剂的标准是什么?
  Collet博士:第一个标准是药物要有PCI的适应证。如果有适应证,就没有问题。第二个标准是当地的报销限制,因为新药的价格昂贵,并不是很多地方都能报销。
  假设有药同时没有报销限制,那么药物的选择将取决于患者的风险。如果是超过适应证的使用范围,有时候可能会有这种情况,你就需要详细评价患者的氯吡格雷抵抗情况。你可能接诊了一位像糖尿病患者这样的极高危患者,患者接受了常规的介入治疗,服用了氯吡格雷,该患者是超重的,可能很适合应用P2Y12抑制剂。
  举例说明,支架血栓。有些患者可能有支架血栓形成史,就诊时已经应用了包括氯吡格雷在内的双联抗血小板治疗,这些患者因为可能会面临新的支架血栓形成的问题,比较合适换用其他抗血小板药物。
  我认为我们应当明确一些简单的临床特点与氯吡格雷抵抗相关,包括糖尿病、急性冠状动脉综合征的表现和病变类型,然后决定选择哪种治疗是非常容易的。
[1]  [2]  下一页

版面编辑:赵书芳  责任编辑:聂会珍



P2Y12受体拮抗剂Jean-Philippe Collet双联抗血小板治疗

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530